Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Employee Benefits topic
No spam. Unsubscribe anytime.
Putnam commissioners table proposal to subsidize GLP‑1 drugs, send issue to insurance committee
Summary
After a lengthy debate about costs, equity and pharmacy benefit management, the Putnam County commission voted to table a proposal to subsidize GLP‑1 weight‑loss medications for employees and asked the insurance committee to study costs and alternatives.
Putnam County commissioners on Tuesday voted to table a proposal that would have provided a $200 per‑vial subsidy toward certain GLP‑1 weight‑loss medications for county employees, sending the matter back to the county's insurance committee for further study.
The proposal drew sustained debate spanning safety, fiscal exposure and fairness. Commissioner Harvey urged expanded review of drugs not covered by the county's primary plan and asked the insurance committee to “look at providing the same sort of coverage the same amount for those drugs not covered by Florida Blue after the appeals process is exhausted.” Commissioner Alexander and others said the county lacks a firm estimate of how many employees would participate and how much the program would cost in the short term.
County human‑resources and benefits staff cautioned that overturning pharmacy‑benefit manager (PBM) decisions risks duplicative spending and inconsistent access. "I would caution the board and the insurance committee against overturning appeals," said Miss Young, the county benefits lead, noting that appeals follow FDA guidance and PBM clinical rules. She suggested alternatives such as a flat county contribution into employees' flexible‑spending accounts.
Opponents warned the plan could undermine the county's PBM and create inequities across plan tiers. One commissioner summarized the fiscal and administrative concerns: the county could be "paying to say no, then we're paying again to say yes," and layered programs could weaken negotiating leverage with vendors.
Supporters argued the drugs can generate long‑term health savings. "It will save us money in a substantial way" over time, said one commissioner who favored measured implementation and additional committee review.
The board adopted a motion to table the item and refer it to the insurance committee for further review, with staff asked to return with cost estimates, program design options and legal guidance on plan interactions and appeals. The committee will analyze immediate fiscal exposure, projected uptake and potential alternatives such as targeted stipends or FSA loading.
